Sun Pharma Advanced Research Co FCO/Dettes

Que fait Sun Pharma Advanced Research Co ? Sun Pharma Advanced Research Co Ltd, listed on the National Stock Exchange of India with ticker SPARC.NS and ISIN INE232I01014, is a pharmaceutical company headquartered in Mumbai, India. The company operates within the healthcare sector, specifically in the pharmaceutical industry, and employs 407 full-time staff. It completed its initial public offering on July 18, 2007. Sun Pharma Advanced Research focuses on research and development of pharmaceutical products targeting unmet medical needs, particularly in the fields of oncology, neurodegeneration, and immunology. The company develops New Chemical Entities (NCEs), New Biological Entities, and reformulated products. Specific NCEs mentioned include SCC-138, SCO-088, SCO-120, and SCD-044. It also utilizes Novel Drug Delivery Systems (NDDS), such as Wrap Matrix Technology for controlled-release tablets, Lipexelle technology for ophthalmic formulations, and TearAct Technology for eye drops. Products developed using these technologies include Elepsia XR, which employs Wrap Matrix Technology, and Xelpros, a BAK-free latanoprost eye drop developed with Lipexelle technology and commercialized in the United States by a partner. Additionally, the company has created PDP-716 eye drops for glaucoma treatment using TearAct Technology. The company's website is https://www.sparc.life/. Sun Pharma Advanced Research Co est l'une des entreprises les plus populaires sur Eulerpool.